Mustafa Raoof, MD, MS

home / authors / mustafa-raoof-md-ms

Articles

Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.

PIPAC-MMC Shows Efficacy in Multiple Response Criteria for Peritoneal Metastases

Mustafa Raoof, MD, MS
April 3rd 2025

Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.

Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.

Peritoneal Tumor Treatment Enhanced by Pre-PIPAC-MMC Small Incision Surgery

Mustafa Raoof, MD, MS
April 2nd 2025

Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.

Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.

Intraperitoneal Therapy Seeks to Address “Nihilism” Around Peritoneal Mets

Mustafa Raoof, MD, MS
April 1st 2025

Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Disease control following radiotherapy appeared to be optimal in a retrospective cohort of patients with multiple myeloma.
Published: April 21st 2025 | Updated: April 26th 2025
Extent of Prior Therapy Does Not Impact Radiotherapy Response in Myeloma